PLRX

Business Context and Reporting Period

Pliant Therapeutics, Inc. (PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for fibrotic diseases and oncology. This Form 10-Q covers the quarterly period ended June 30, 2025. The company operates as a single reportable segment and is headquartered in South San Francisco, California.

Key Financial Metrics

Note: Revenue is $0 as the company has no approved products for commercial sale. Cash and investments are derived from the balance sheet ($86,820 cash + $176,053 short-term investments).

Material Changes vs. Prior Period

• Discontinuation of Lead Program: In June 2025, the company announced the discontinuation of bexotegrast development for Idiopathic Pulmonary Fibrosis (IPF) following the BEACON-IPF Phase 2b/3 trial, which demonstrated an unfavorable risk-benefit profile due to safety event imbalances.
• Cost Reductions: Research and Development (R&D) expenses decreased by $13.4 million in Q2 2025 compared to Q2 2024, primarily driven by the cessation of the BEACON-IPF trial and a workforce reduction.
• Restructuring: In May 2025, the company initiated a restructuring plan impacting approximately 45% of its workforce. Total one-time termination benefits recorded were $3.8 million ($2.7 million in R&D and $1.0 million in G&A).
• Interest Income: Interest and other income decreased by $2.6 million in Q2 2025 compared to the prior year, attributable to lower investment balances as cash was utilized to fund operations.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring net losses for the foreseeable future. The company believes its existing capital resources ($264.4 million in cash and investments as of June 30, 2025) are sufficient to fund operations for the next 12 months and beyond.
• Pipeline Focus: Following the IPF discontinuation, the company is prioritizing:
  • PLN-101095: A Phase 1 trial for solid tumors resistant to immune checkpoint inhibitors is currently enrolling the fifth of five dose cohorts.
  • PLN-101325: A Phase 1-ready monoclonal antibody for muscular dystrophies (including Duchenne muscular dystrophy) which has received clinical trial approval in Australia.
• Debt Covenants: The company holds a $30.0 million term loan with Oxford Finance LLC. Due to the discontinuation of the BEACON-IPF trial, the company does not expect to have access to additional borrowings under the amended loan agreement, as availability was contingent on the continued development of bexotegrast in IPF.
• Key Risks:
  • Dependence on the success of early-stage product candidates with no revenue stream.
  • Need for substantial additional capital to fund future operations and clinical trials.
  • Reliance on third-party suppliers, including single-source vendors in foreign jurisdictions (e.g., China), for manufacturing.
  • Intellectual property protection and potential infringement claims.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $264.4 million cash position against the revised burn rate post-restructuring and the timeline for the next capital raise.
• Debt Status: Confirm the terms of the Oxford Finance loan, specifically the inability to draw additional funds and the repayment schedule (maturity March 1, 2029).
• Restructuring Costs: Review the remaining accruals for termination benefits ($0.5 million as of June 30, 2025) and the actual impact on future operating expenses.
• Pipeline Progress: Monitor enrollment and safety data for the PLN-101095 Phase 1 trial and regulatory milestones for PLN-101325.
• Stockholder Rights Plan: Note the adoption of a poison pill (Stockholder Rights Agreement) in March 2025, which may impact potential M&A activity.